Navigation Links
DFH Pharma to Collaborate With National Cancer Institute to Develop Second-Generation HIV Maturation Inhibitor Drugs
Date:1/10/2012

GAITHERSBURG, Md., Jan. 10, 2012 /PRNewswire-iReach/ -- DFH Pharma, Inc., (DFH) a privately held specialty pharmaceutical company focused exclusively in the HIV-1 therapeutic space, announced today a collaborative agreement between DFH and the National Cancer Institute (NCI) to further the development of the next generation of HIV maturation inhibitor drugs. Maturation inhibitors are a novel class of antiretroviral drug candidates that inhibit HIV-1 replication by interfering with the maturation of the HIV-1 virus.

The collaboration will involve extending successful efforts by DFH Pharma to identify drug candidates with potent activity against all HIV strains, including those that proved resistant to the first-in-class maturation inhibitor, bevirimat. DFH scientists have identified a series of 2nd generation maturation inhibitors with the broad anti-viral activity profile necessary for successful HIV drug development. The NCI investigators will evaluate the activity of these compounds against HIV strains associated with reduced bevirimat activity. The most potent of these compounds will be selected for further pre-clinical testing with a goal of initiating human clinical trials with one or more candidate molecules in the near future.

Dr. Eric Freed, an internationally recognized leader in the field of HIV assembly and release, will head the NCI group. Dr. Freed has worked in the maturation inhibition area since the early 2000's when his group collaborated with Panacos Pharmaceuticals in the discovery and characterization of the maturation inhibitor class of HIV drugs. "We are very excited to be working with Dr. Freed and his NCI colleagues in developing this new class of drugs to treat HIV infection"' said Carl Wild, Ph.D., President and CEO. Dr. Wild continued, "The NCI collaboration will allow DFH to build on its recent success in identifying broadly active maturation inhibitor drug can
'/>"/>

SOURCE DFH Pharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Sigma-Aldrich to Acquire BioReliance; Extending Its Reach into Biopharmaceutical Testing and Services
2. SFJ Pharma Ltd. II, Announces Agreement With Pfizer to Develop Axitinib for Adjuvant Treatment of Renal Cell Carcinoma
3. Reata Pharmaceuticals to Present at 30th Annual J.P. Morgan Healthcare Conference
4. HealthCare Institute of New Jersey Releases 2011 Biopharmaceutical and Medical Technology Economic Impact Data
5. Keryx Biopharmaceuticals to Present at JP Morgans 30th Annual Healthcare Conference
6. Inovio Pharmaceuticals Promotes Niranjan Sardesai to Chief Operating Officer
7. Amylin Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
8. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
9. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
10. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
11. PAREXEL Introduces Executive Briefing Series on Proven Practices to Assist Emerging and Mid-size Biopharma in Achieving Better Outcomes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... 21, 2015 A leading manufacturer of ... slated to discuss its custom fabrication services today at ... website, which launched just prior to the INTERPHEX event. ... 21, 22 and 23) at the Javits Center in ... the world’s largest and most innovative pharmaceutical and biotech ...
(Date:4/20/2015)... and MENLO PARK, Calif. , ... (OTCQX: DMPI) (DelMar and the Company), a ... cancer therapies in new orphan drug indications, today ... Annual Meeting of the American Association for Cancer ... for its lead product candidate VAL-083 ...
(Date:4/20/2015)... Calif. , April 20, 2015 PointCross ... Pvt. Ltd. to provide an integrated Big Data and ... all biomarkers collected in the context of clinical trials ... of precise or multi-targeted drug candidates, stratified patient selection ... disease progression free survival. Highlighting the ...
(Date:4/20/2015)... - Portage Biotech Inc. ("Portage" or "the Company") (OTC ... announce that its wholly owned subsidiary, Portage Pharmaceuticals Ltd. ... one of its proprietary human-derived CPP sequences and a ... of NFkB signalling even if administered when the BBB ... blood brain barrier (BBB) in mice was studied and ...
Breaking Biology Technology:HOLLOWAY AMERICA to Reveal Newly Designed Responsive Website at INTERPHEX 2015 Today 2HOLLOWAY AMERICA to Reveal Newly Designed Responsive Website at INTERPHEX 2015 Today 3DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 2DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 3DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 4DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 5PointCross Life Sciences and InterpretOmics partner for Clinical and Genomic Biomarker Management for Drug Development 2Portage's CPP Platform Delivers a Peptide Cargo Across Blood Brain Barrier 2Portage's CPP Platform Delivers a Peptide Cargo Across Blood Brain Barrier 3
... , a provider of molecular diagnostics solutions, reported losses in ... Wave reported total revenue of $5.8 million and a net ... for the quarter ended June 30, 2005, compared to total ... and zero cents per diluted share for the same period ...
... Third Wave Technologies Inc., a developer and provider ... chairman of the company's board of directors, replacing company ... the business's planned transition. , ,Thompson, 63, was the ... of Abbott Laboratories , an Illinois-based medical products ...
... Corp ., a Waukesha-based supply chain technology ... enabling Cooper Lighting , a George-based ... distribution operations and workforce productivity. , ,The ... with RedPrairie's DLx Warehouse, slotting and workforce ...
Cached Biology Technology:Transition continues to impact Third Wave financials 2
(Date:4/2/2015)... Fingerprint Cards (FPC) has received ... the distributor World Peace Industrial Group (WPI), part of ... the major part of the shipments will take place ... smartphone manufacturers in China . The ... communicated revenue guidance of + 1 000 MSEK for 2015.  ...
(Date:3/30/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/lc9bnl/global_gesture ) has ... Market in Automotive Sector 2014-2018" report to their ... Recognition market in Automotive Sector to grow at a ... Gesture recognition is the ability of a device to ... Gesture recognition technology can be 2D-based or 3D-based. It ...
(Date:3/24/2015)... GARDENS, Fla. , March 24, 2015 /PRNewswire/ ... identity management solutions, today announced that its U.are.U ... clothing accessory retailer Goorin Bros . to ... Crossmatch biometrics-based solution secures access to the POS ... the increased risk of data breaches. ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2
... of a new gene is helping researchers at Michigan ... A team of researchers, led by Katherine Osteryoung, ... a new class of proteins in the ... Academy of Sciences . CLMP1 plays a key role ...
... aid cavity-nesting ducks can prove to be turtle death traps. ... Educator Associate Professor Denis Conover, of the Department of Biological ... he came upon a duck nest box in the wetlands ... over. Turtle corpses were strewn about the mud and mire ...
... living in family or group homes are less ... living in institutions, according to University of Louisville ... Ph.D. These individuals also are more likely than ... increased decay and gum disease, factors that may ...
Cached Biology News:Discovery of new gene could improve efficiency of molecular factories 2UC research finds that a duck's boon might be a turtle's bane 2UofL researcher to develop oral health plan for those with IDD 2
... Hot Start Taq ... activity before the onset ... nonspecific amplification and primer-dimer ... is raised, the antibody ...
... Fluorescein 6-Fam, Hex, Tet Cy3, Cy5, ... Tamra Black Hole Quenchers Molecular Beacons* ... Tamra, Joe 3 Dabcyl Dabcyl*Licensed ... York Double labelled probes are purified either ...
... (rEK) is a highly purified preparation of ... serine protease which recognizes the identical cleavage ... has similar enzymatic activity (1). Novagen&'s enzyme ... to yield the highest activity available, and ...
Angiotensin Converting Enzyme [Porcine Kidney, ACE, Peptidyl-dipeptidase A]...
Biology Products: